Skip to content
OpenCapital
Get started

Novanta NOVT Medical Solutions — Research And Development Expense

Other segment segments

Automation Enabling Technologies
$9.03M-4.3%

Similar metrics at other companies

Medtronic logo
MDTMedical Surgical — Research and development expense
$163M-3.6%
Becton, Dickinson and Company logo
BDXMedical Essentials — Research and development expense
$53M+10.4%
Becton, Dickinson and Company logo
BDXMedical — Research and development expense
$130.75M+17.0%
Baxter International logo
BAXMedical Products & Therapies — Research and development expenses
$54M-8.5%
Boston Scientific logo
BSXMedSurg — Research and development expenses
$127M+5.0%
Resideo Technologies, Inc. logo
REZIProducts and Solutions — Research and development expenses
$36M+33.3%

Other financials

Income statement

See full
Revenue$257.7M+10.4%
Gross profit$113.6M+8.8%
Operating income$27.5M-15.1%
Net income$21.1M-0.5%
EPS (diluted)$0.51-13.6%

Balance sheet

See full
Cash & equivalents$388.8M+267%
Total debt$291.3M-34.2%
Total equity$1.3B+70.3%
Total assets$1.8B+29.9%

Cash flow

See full
Operating cash flow$51.6M+62.9%
CapEx$4.1M-3.4%
Free cash flow$47.5M+73.2%

Valuation

See full
Market cap$5.53B-8.3%

Profitability

See full
Gross margin44.2%-0.5pp
Operating margin8.9%-3.5pp
Net margin5.3%-2.1pp
FCF margin6.8%-8.1pp

Returns & leverage

See full
Return on equity5.2%-4.6pp
Debt / equity0.2×-0.4×
Current ratio3.6×+1.0×

Where this comes from

Reported directly by Novanta in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Novanta’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novanta's medical solutions — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novanta's medical solutions — research and development expense?
Novanta (NOVT) reported medical solutions — research and development expense of $14.25M in Q1 2026.
How has Novanta's medical solutions — research and development expense changed year-over-year?
Novanta's medical solutions — research and development expense increased by 2.1% year-over-year, from $13.96M to $14.25M.
What is the long-term trend for Novanta's medical solutions — research and development expense?
Over 3 years (2022 to 2025), Novanta's medical solutions — research and development expense has grown at a 13.0% compound annual growth rate (CAGR), from $40.42M to $58.34M.
What does medical solutions — research and development expense mean?
Costs incurred by the Medical Solutions segment to develop new products, improve existing technologies, and advance scientific capabilities. This investment is critical for maintaining long-term competitive advantage and innovation within the medical device or solutions market.